Cardiovascular Therapies Stocks
Specialized developers and manufacturers in this sector focus on the high-stakes prevention, diagnosis, and treatment of heart disease and vascular disorders through advanced medical devices, biologics, and targeted pharmaceuticals.
As of Oct 23, 2026, Cardiovascular Therapies has 65 US-listed companies worth $1.5T combined. The median member moved +2.0% over the past week; LQDA led among the 25 largest at +24.2% and ALNY trailed at -3.4%.
Companies in Cardiovascular Therapies
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- AMGN – Amgen Inc, $237B
- ABT – Abbott Laboratories, $177B
- BMY – Bristol-Myers Squibb Company, $129B
- MDT – Medtronic PLC, $122B
- BSX – Boston Scientific Corp, $66.7B
- EW – Edwards Lifesciences Corp, $51.9B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- BBIO – BridgeBio Pharma Inc, $13.4B
- PEN – Penumbra Inc, $12.8B
- CYTK – Cytokinetics Inc, $8.5B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- TFX – Teleflex Incorporated, $5.5B
- HAE – Haemonetics Corporation, $5.4B
- MMSI – Merit Medical Systems Inc, $5.4B
- HTFL – Heartflow, Inc. Common Stock, $4.4B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- ITGR – Integer Holdings Corp, $4.3B
- LIVN – LivaNova PLC, $4.3B
- IRTC – iRhythm Technologies Inc, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- ATRC – AtriCure Inc, $3B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- BRVE – Braveheart Bio, Inc. Common Stock, $1.9B
- KMTS – Kestra Medical Technologies, Ltd. Common Stock, $1.7B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- AORT – Artivion Inc, $1.1B
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- AVR – Anteris Technologies Global Corp. Common Stock, $629M
- SLN – Silence Therapeutics PLC, $613M
- OBIO – Orchestra BioMed Holdings Inc., $358M
- AMRN – Amarin Corporation PLC, $261M
- IKT – Inhibikase Therapeutics Inc, $251M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- NNNN – Anbio Biotechnology Class A Ordinary Shares, $205M
- CRDL – Cardiol Therapeutics Inc Class A, $146M
- RNA – Atrium Therapeutics, Inc. Common Stock, $130M
- MIST – Milestone Pharmaceuticals Inc, $98.2M
- TNYA – Tenaya Therapeutics Inc, $87.5M
- TENX – Tenax Therapeutics Inc, $50.9M
- VERU – Veru Inc, $41.9M
- CVRX – CVRx Inc, $36M
- ELUT – Elutia Inc., $34.2M
- BEAT – Heartbeam Inc, $22.6M
- NSPR – InspireMD Inc, $22.3M
- PMI – Picard Medical, Inc., $17.2M
- HSCS – Heart Test Laboratories Inc. Common Stock, $16.5M
- BCDA – Biocardia Inc, $15.7M
- MTVA – MetaVia Inc., $9.6M
- LEXX – Lexaria Bioscience Corp, $5.5M
- NVNO – enVVeno Medical Corp, $5.4M
- CDIO – Cardio Diagnostics Holdings Inc, $5.2M
- CVKD – Cadrenal Therapeutics, Inc. Common Stock, $4.1M
- ADGM – Adagio Medical Holdings, Inc Common Stock, $3.2M
- XRTX – XORTX Therapeutics Inc, $2.3M
- NUWE – Nuwellis Inc, $2M
- BTCY – Biotricity Inc, $1M
- ZVSA – ZyVersa Therapeutics Inc., $647,673
- VTAK – Catheter Precision Inc., $286,477
- WINT – Windtree Therapeutics Inc, $33,708
- AFIB – Acutus Medical Inc, $2,991
- RTSN – Retension Pharmaceuticals, Inc.